In the first year after the expiration of performance commitments, that is, 2019, Tokunobu Kenyasuko company's Jialin pharmaceutical performance declined sharply, resulting in the company's reporting period, net profit attributable to shareholders of listed companies, and net profit and loss excluding non recurring gains and losses attributable to shareholders of listed companies fell by 46.06%, 63.79% and 72.38% respectively.